MedTrace Logo

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

NCT06055348 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2023-09-26

No results posted yet for this study

Summary

A phase Ib/II clinical study on the safety, pharmacokinetic characteristics, and preliminary efficacy of SC0191 combination chemotherapy in patients with advanced ovarian cancer.

Conditions

  • Serous Ovarian Cancer
  • Advanced Ovarian Cancer

Interventions

DRUG

SC0191

SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.

DRUG

Paclitaxel

Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.

Sponsors & Collaborators

  • Biocity Biopharmaceutics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2025-08-30
Completion
2025-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055348 on ClinicalTrials.gov